

Marianna Koczywas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3156008/publications.pdf>

Version: 2024-02-01

67
papers

1,286
citations

394421

19
h-index

377865

34
g-index

67
all docs

67
docs citations

67
times ranked

1902
citing authors

#	ARTICLE	IF	CITATIONS
1	Interdisciplinary Palliative Care for Patients With Lung Cancer. <i>Journal of Pain and Symptom Management</i> , 2015, 50, 758-767.	1.2	155
2	Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2022, 12, 74-89.	9.4	133
3	Effectiveness of an interdisciplinary palliative care intervention for family caregivers in lung cancer. <i>Cancer</i> , 2015, 121, 3737-3745.	4.1	110
4	Defining a standard set of patient-centred outcomes for lung cancer. <i>European Respiratory Journal</i> , 2016, 48, 852-860.	6.7	88
5	Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, e1025-e1034.	2.5	83
6	Geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer: A randomized controlled trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 12010-12010.	1.6	75
7	EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , 2022, 23, 758-767.	10.7	49
8	Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation. <i>Journal of Clinical Oncology</i> , 2018, 36, 8515-8515.	1.6	44
9	Understanding Caregiver Quality of Life in Caregivers of Hospitalized Older Adults With Cancer. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 978-986.	2.6	36
10	A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. <i>Frontiers in Oncology</i> , 2020, 10, 578756.	2.8	36
11	Longitudinal Changes in Function, Symptom Burden, and Quality of Life in Patients with Early-Stage Lung Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 1788-1797.	1.5	35
12	Long-Term Effect of an Interdisciplinary Supportive Care Intervention for Lung Cancer Survivors After Surgical Procedures. <i>Annals of Thoracic Surgery</i> , 2016, 101, 495-503.	1.3	33
13	Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2015, 121, 3298-3306.	4.1	32
14	Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival. <i>Journal of Thoracic Disease</i> , 2020, 12, 5086-5095.	1.4	29
15	Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20). <i>Journal of Clinical Oncology</i> , 2021, 39, 9077-9077.	1.6	29
16	Interdisciplinary Palliative Care Intervention in Metastatic Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 736-744.	2.6	24
17	Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2021, 39, 9007-9007.	1.6	24
18	A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER. <i>Journal of Clinical Oncology</i> , 2018, 36, 9025-9025.	1.6	23

#	ARTICLE	IF	CITATIONS
19	Phase 1B Study of Mometinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure. <i>Clinical Lung Cancer</i> , 2018, 19, e853-e859.	2.6	21
20	Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio. <i>Lung Cancer</i> , 2019, 133, 136-143.	2.0	21
21	Dissemination and Implementation of Palliative Care in Oncology. <i>Journal of Clinical Oncology</i> , 2020, 38, 995-1001.	1.6	17
22	Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma. <i>Journal of Clinical Oncology</i> , 2020, 38, 9058-9058.	1.6	16
23	Pulmonary Rehabilitation and Palliative Care for the Lung Cancer Patient. <i>Journal of Hospice and Palliative Nursing</i> , 2015, 17, 462-468.	0.9	15
24	A Palliative Care Intervention for Patients on Phase 1 Studies. <i>Journal of Palliative Medicine</i> , 2021, 24, 846-856.	1.1	15
25	Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. <i>Cancer Treatment and Research Communications</i> , 2019, 21, 100155.	1.7	13
26	The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1183-1188.	1.1	12
27	Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 1429.	2.4	12
28	Spirituality in cancer patients on phase 1 clinical trials. <i>Psycho-Oncology</i> , 2020, 29, 1077-1083.	2.3	9
29	Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. <i>Cancers</i> , 2021, 13, 2776.	3.7	9
30	A nurse-led intervention for fear of cancer progression in advanced cancer: A pilot feasibility study. <i>European Journal of Oncology Nursing</i> , 2020, 49, 101855.	2.1	8
31	Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. <i>Lung Cancer</i> , 2020, 146, 174-181.	2.0	8
32	Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e257-e265.	2.9	8
33	The Association between Polluted Neighborhoods and TP53-Mutated Non-Small Cell Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1498-1505.	2.5	8
34	Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa067.	2.9	7
35	Precision medicine and actionable alterations in lung cancer: A single institution experience. <i>PLoS ONE</i> , 2020, 15, e0228188.	2.5	7
36	Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance: A California Cancer Consortium Phase II Trial (NCI 9303). <i>Journal of Clinical Oncology</i> , 2015, 33, 8087-8087.	1.6	7

#	ARTICLE	IF	CITATIONS
37	SWOG S1206: A dose-finding study of veliparib (ABT-888) added to chemoradiotherapy (CRT) with carboplatin (C) and paclitaxel (P) for unresectable stage III non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 8537-8537.	1.6	6
38	Integration of palliative care for patients with solid tumors on phase I clinical trials.. Journal of Clinical Oncology, 2016, 34, 138-138.	1.6	6
39	ARQ 197 in patients with previously-treated malignant mesothelioma (MM): A phase II trial from the University of Chicago Phase II Consortium.. Journal of Clinical Oncology, 2015, 33, 7511-7511.	1.6	5
40	Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer. Cureus, 2021, 13, e16266.	0.5	4
41	S1206: A dose-finding study followed by a phase II randomized placebo-controlled trial of chemoradiotherapy (CRT) with or without veliparib in stage III non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, 8523-8523.	1.6	3
42	Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. Cancers, 2021, 13, 2653.	3.7	2
43	Abstract LB050: Modulation of innate and adaptive immunity in blood and tumor of patients receiving the SHP2 inhibitor RMC-4630. , 2021, , .		2
44	A randomized trial of a palliative care intervention for patients on phase I studies.. Journal of Clinical Oncology, 2020, 38, 12001-12001.	1.6	2
45	Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations. Future Science OA, 2021, 7, FSO662.	1.9	1
46	Phase IIa study of marrow infiltrating lymphocytes (MILs), an adoptive T cell therapy, alone or in combination with nivolumab in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, TPS9630-TPS9630.	1.6	1
47	Goals of care and advanced care planning in phase I trials.. Journal of Clinical Oncology, 2018, 36, 80-80.	1.6	1
48	Patient perspectives on participation in phase 1 clinical trials.. Journal of Clinical Oncology, 2019, 37, 48-48.	1.6	1
49	Family Caregiver Preparedness: Developing an Educational Intervention for Symptom Management. Clinical Journal of Oncology Nursing, 2022, 26, 165-175.	0.6	1
50	Feasibility of administering a geriatric assessment to older adults with cancer using web-based and touchscreen platforms.. Journal of Clinical Oncology, 2015, 33, 9536-9536.	1.6	0
51	Interdisciplinary palliative care for patients with lung cancer.. Journal of Clinical Oncology, 2015, 33, 130-130.	1.6	0
52	KRAS in non-small cell lung cancer: Single institution experienceâ€”What factors are involved?. Journal of Clinical Oncology, 2017, 35, 11624-11624.	1.6	0
53	The integrated care service: Impact of a multidisciplinary supportive care service for medical oncology patients in a NCI-designated cancer center.. Journal of Clinical Oncology, 2018, 36, 134-134.	1.6	0
54	Precision medicine and actionable alterations in lung cancer.. Journal of Clinical Oncology, 2019, 37, e20707-e20707.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Identifying patient-reported anxiety and depression in older adults with cancer.. Journal of Clinical Oncology, 2019, 37, 11556-11556.	1.6	0
56	Molecular and clinical features of hospital admissions and immunotherapy related adverse events of immune checkpoint inhibitors in thoracic malignancies.. Journal of Clinical Oncology, 2019, 37, e18192-e18192.	1.6	0
57	Germline mutations and onset of lung adenocarcinoma in smokers and nonsmokers.. Journal of Clinical Oncology, 2019, 37, 1518-1518.	1.6	0
58	Precision medicine for lung cancer decision-making: Evaluation of an -omics based FFT approach to personalized medicine.. Journal of Clinical Oncology, 2019, 37, e20713-e20713.	1.6	0
59	Validity of patient-reported outcomes to describe the symptom experience of patients enrolled on phase I clinical trials.. Journal of Clinical Oncology, 2020, 38, 12107-12107.	1.6	0
60	Alterations in STK11 to limit response to immune checkpoint inhibitors in lung cancer.. Journal of Clinical Oncology, 2020, 38, e21503-e21503.	1.6	0
61	Phase I study of TRC102 in combination with cisplatin and pemetrexed in patients with advanced solid tumors/Phase II study of TRC102 with pemetrexed in patients with mesothelioma refractory to pemetrexed and cisplatin or carboplatin.. Journal of Clinical Oncology, 2020, 38, 9055-9055.	1.6	0
62	Evaluation of immune-related adverse events in patients treated with sequential immunotherapy and tyrosine kinase inhibitor treatment in non-small cell lung cancer.. Journal of Clinical Oncology, 2020, 38, e21562-e21562.	1.6	0
63	Patient-defined goals and preferences among adults with advanced neuroendocrine tumors.. Journal of Clinical Oncology, 2022, 40, 509-509.	1.6	0
64	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
65	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
66	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
67	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0